A synthetic six-amino-acid peptide that stimulates growth hormone release through the ghrelin receptor, from the same research generation as GHRP-2. It is described as among the most potent of the early secretagogues.

What does desensitisation mean here?

The growth hormone response diminishes with continued exposure. Receptors exposed to a strong unrelenting signal turn their own sensitivity down — the same reason a strong smell fades after a few minutes in a room. Hexarelin shows this more markedly than others in its family.

What is CD36 and why does it matter?

A receptor present on cardiac tissue that Hexarelin binds and the other GHRPs largely do not. It opened a research line into cardiac effects that appears to operate independently of growth hormone release — some studies report effects in animals whose GH response was already blunted.

How does Hexarelin compare with Ipamorelin?

Hexarelin is described as more potent at releasing growth hormone but shows markedly greater desensitisation and lacks Ipamorelin’s selectivity. Ipamorelin was characterised for releasing growth hormone without meaningfully affecting cortisol or prolactin.

Research Library›Growth Hormone & Endocrine›Hexarelin

GHRP / Cardiac Research

Hexarelin: The Secretagogue That Went Somewhere Else

The most potent of the early growth hormone peptides, and the one whose research drifted away from growth hormone entirely — into cardiac tissue, through a receptor the rest of the family does not use.

6 min read·4 studies cited·Updated July 2026

Evidence level

Human trial evidence exists — no regulatory approval

What this level means

Quick Reference

Class	GHRP — ghrelin receptor agonist
Generation	Same era as GHRP-2
Distinctive trait	Marked desensitisation with continued use
Secondary receptor	CD36 — cardiac tissue
Studied for	GH release and, separately, cardioprotection

What Is Hexarelin?

Hexarelin is a synthetic hexapeptide from the same generation of research as GHRP-2, acting on the ghrelin receptor to prompt growth hormone release. Published work describes it as among the most potent of the early secretagogues at doing so.

It is also the family member whose story diverges most sharply from the others, for two reasons: it desensitises unusually quickly, and it interacts with a receptor the rest of the family does not.

The Compound That Stops Listening

Hexarelin is documented as producing pronounced desensitisation — the growth hormone response diminishes with continued exposure more markedly than with other compounds in the family.

Desensitisation, in plain language: walk into a bakery and the smell of bread is overwhelming. Ten minutes later you barely notice it — the bread has not changed, your receptors have simply stopped reporting it. Biological systems do this constantly, because a signal that never varies carries no information. A receptor exposed to a strong, unrelenting stimulus turns its own volume down.

This is a genuinely useful thing to understand about the whole class, because it explains why the research literature discusses these compounds in terms of pulses and patterns rather than simply amounts. A system built to respond to rhythm does not respond well to a constant tone.

The Second Receptor: CD36

The more interesting divergence is that Hexarelin binds CD36, a receptor found on cardiac tissue and elsewhere, which the other GHRPs do not engage in the same way.

That opened a research line largely separate from growth hormone. Studies have examined Hexarelin in models of cardiac stress and injury, looking at effects on heart tissue that appear to run through CD36 rather than through the growth hormone axis. Some of this work reports cardioprotective effects in animals whose growth hormone response had already been blunted — which points to a mechanism operating independently of GH release.

So Hexarelin ends up in the odd position of being catalogued as a growth hormone secretagogue while a substantial part of its research literature is about something else entirely.

Where the Evidence Stands

Hexarelin has a solid preclinical literature across both research lines, with some early human characterisation of its growth hormone effects. The cardiac work is mostly animal and cell-level.

It holds no regulatory approval in any jurisdiction. The desensitisation finding is well documented and is one of the clearer practical distinctions between family members in the published record.

Frequently Asked Questions

Compiled by the Southern Pacific Labs research team. Last updated July 2026.

Browse the research range →

Published References

Bowers CY. “Growth hormone-releasing peptide (GHRP).” Cellular and molecular life sciences : CMLS, 1998. PubMed
Berlanga-Acosta J, Abreu-Cruz A, Herrera DGB, et al. “Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects.” Clinical Medicine Insights. Cardiology, 2017. PubMed
Bodart V, Febbraio M, Demers A, et al. “CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart.” Circulation research, 2002. PubMed
Raun K, Hansen BS, Johansen NL, et al. “Ipamorelin, the first selective growth hormone secretagogue.” European journal of endocrinology, 1998. PubMed